LivingGLP1
parallel randomized trial

S003039

Design

Randomized
22
Start year
2016
Treatment
24 weeks, follow-up 24 weeks
Countries
Japan
Sponsor
(non industry)
Eligibility
T2D age 20 or older; HbA1c 6.5 percent or higher; liraglutide for at least 12 weeks; eGFR 30 or higher

Conduct and analysis

Blinding
open label
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
completers
Missing data
none

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1dulaglutide
Switch to dulaglutide
liraglutide stopped; other glucose lowering drugs and insulin unchanged; lifestyle: standard1111
A2liraglutide
Continue liraglutide
other glucose lowering drugs and insulin unchanged; lifestyle: standard1111

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticSwitch to dulaglutide
A1
Continue liraglutide
A2
agemean (years)69.267.8
agesd (years)9.19.5
bmimean (kg/m2)26.725.9
bmisd (kg/m2)4.43.6
diabetes durationmean (years)14.513.7
diabetes durationsd (years)8.98.2
egfrmean (mL/min/1.73 m2)71.576.6
egfrsd (mL/min/1.73 m2)18.019.2
established cvdn52
established cvdpercent45.518.2
hba1cmean (percent)7.17.2
hba1csd (percent)0.50.5
insulin usen38
insulin usepercent27.372.7
metformin usen55
metformin usepercent45.545.5
other agi usen51
other agi usepercent45.59.1
other glinide usen01
other glinide usepercent0.09.1
other malen94
other malepercent81.836.4
other sulfonylurea usen10
other sulfonylurea usepercent9.10.0
other thiazolidinedione usen11
other thiazolidinedione usepercent9.19.1
sbpmean (mmHg)137.5138.5
sbpsd (mmHg)17.519.1
sglt2i usen12
sglt2i usepercent9.118.2
weightmean (kg)68.363.4
weightsd (kg)13.412.9

Analyses this trial contributes to

Results

8 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (2 lines; O01)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
24A1final7.1 percent0.611not stated; completers; R0019432:Table 2
24A2final7.6 percent0.911not stated; completers; R0019432:Table 2
Body weight change in kilograms (diabetes) (2 lines; O02)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
24A1final69.1 kg14.011not stated; completers; R0019432:Table 2
24A2final64.4 kg13.811not stated; completers; R0019432:Table 2
Systolic blood pressure change (2 lines; O05)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
24A1final136.8 mmHg20.211not stated; completers; R0019432:Table 2
24A2final131.6 mmHg21.111not stated; completers; R0019432:Table 2
Health related quality of life total score (any instrument) (2 lines; O24C)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
24A1final30.00 points5.6011not stated; completers; R0019432:Table 3
24A2final26.36 points3.9811not stated; completers; R0019432:Table 3